
ADARx Pharmaceuticals, Inc. ($ADRX) announced an update on their ongoing clinical study. Study Overview: ADARx Pharmaceuticals, Inc. is evaluating its Phase 2 study, officially titled “A Phase 2 Study to
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ADRX | ADARx Pharmaceuticals | 12.82 | -5.13 | -28.58% |
| Name | Price | % Change | |
|---|---|---|---|
| $12.82 | -28.58% |

ADARx Pharmaceuticals, Inc. ($ADRX) announced an update on their ongoing clinical study. Study Overview: ADARx Pharmaceuticals, Inc. is evaluating its Phase 2 study, officially titled “A Phase 2 Study to

In a report released on November 13, Michael Ulz from Morgan Stanley maintained a Buy rating on ADARx Pharmaceuticals, with a price target of $32.00. Michael Ulz’s Buy rating is

ADARx Pharmaceuticals, Inc. ($ADRX) announced an update on their ongoing clinical study. Study Overview: ADARx Pharmaceuticals, Inc. (ADRX) is studying ADX-038 in a Phase 2 trial for geographic atrophy linked

The latest announcement is out from ADARx Pharmaceuticals ( ($ADRX) ). On November 12, 2026, ADARx updated its corporate presentation and reported third-quarter 2026 financial results and business updates. In

Reports Q3 revenue $2.22M, consensus $2.58M. “We have made significant progress across our pipeline of next-generation siRNA therapeutics, bolstered by the successful completion of our IPO and concurrent private placement.

LifeSci Capital initiated coverage of ADARx Pharmaceuticals (ADRX) with an Outperform rating and $32 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.

JPMorgan initiated coverage of ADARx Pharmaceuticals (ADRX) with an Overweight rating and $38 price target The firm says the company leverages two technologies to overcome limitations of first-generation approaches in

TD Cowen initiated coverage of ADARx Pharmaceuticals (ADRX) with a Buy rating and no price target The company has a combined $200B total addressable market across its complement, orphan, cardio,

Morgan Stanley initiated coverage of ADARx Pharmaceuticals (ADRX) with an Overweight rating and $32 price target The company has a “derisked”siRNA platform and “robust” clinical stage pipeline, the analyst tells

UBS initiated coverage of ADARx Pharmaceuticals (ADRX) with a Buy rating and $35 price target The firm has conviction in the company’s siRNA platform “with deep and durable target depletion.”
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.